Please assess the completion status of the following clinical trial:

Trial Title: Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 65 years old~* Hemoglobin concentration ≥ 9.0 g/dL and \< 11.5 g/dL (women) or \< 12.7 g/dL (men)~* Unexplained anemia~* Serum ferritin level ≥ 20 and ≤ 200 ng/mL~* Able to walk without the use of a walker, motorized device or the assistance of another person.~* Able to understand and willing to provide written informed consent in the absence of dementia~* Must be able to understand and speak in English~Exclusion Criteria:~* Red blood cell transfusions within the past 3 months~* Use of erythropoiesis stimulating agents (ESA) in the past 3 months~* Intravenous Iron Infusions within the past 3 months~* Distance on baseline 6MWT (6 minute walk test) above the median for age and sex~* History of unstable angina or myocardial infarction in the past 3 months~* History of stroke or TIA (transient ischemic attack) the past 3 months~* Uncontrolled hypertension (diastolic blood pressure \> 100 mm Hg or systolic blood pressure \> 160 mm Hg on 2 separate occasions)~* Positive fecal occult blood test within the screening period~* Elevated AST (aspartate aminotransferase) or ALT (alanine aminotransferase) ≥ 2x upper limit of normal~* Documented anaphylactic reaction to iron sucrose infusion in the past~* Subjects initiated on oral iron supplementation within the last 6 weeks, or those initiated on oral iron within the last 3 months who have had at least a one gram/dL improvement in Hb since starting oral iron supplementation

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Intervention Group (Type: EXPERIMENTAL): Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
- Wait List Control (Type: EXPERIMENTAL): Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up

Based on this trial design, predict the completion outcome and termination type (if applicable).